2024-02-23 11:09:43 ET
Summary
- Novavax, Inc. soars after settling Covid-19 vaccine dispute and positive peer numbers, but the future remains bleak with the cash balance under pressure.
- The settlement with Gavi requires Novavax to pay $475 million through 2028, potentially totaling $700 million in cash and vaccines.
- The company will report Q4 results next week, with the focus on whether Novavax can maintain enough vaccine sales to cover operating expenses to prevent further cash burn.
Novavax, Inc. ( NVAX ) soared on Thursday following the settlement of a Covid-19 vaccine dispute and positive numbers from a peer. The biotech still has a bleak future and the annual settlement payments will pressure cash. My investment thesis remains Bearish on NVAX stock following the big rally....
Read the full article on Seeking Alpha
For further details see:
Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems